Mackenzie Financial Corp Enanta Pharmaceuticals Inc Transaction History

Mackenzie Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $2.27 Million - $3.33 Million	-37,753 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $2.83 Million - $3.39 Million	34,843 Added 1197.35%	37,753 $3.19 Million
Q1 2019 May 15, 2019	SELL	$69.08 - $105.66 $6,217 - $9,509	-90 Reduced 3.0%	2,910 $278,000
Q4 2018 Feb 06, 2019	SELL	$65.41 - $84.65 $1.72 Million - $2.22 Million	-26,275 Reduced 89.75%	3,000 $212,000
Q3 2018 Nov 15, 2018	SELL	$85.46 - $126.37 $513,187 - $758,851	-6,005 Reduced 17.02%	29,275 $2.5 Million
Q2 2018 Aug 13, 2018	BUY	$81.85 - $120.51 $1.39 Million - $2.05 Million	17,000 Added 93.0%	35,280 $4.09 Million
Q1 2018 May 14, 2018	BUY	$57.91 - $92.15 $1.06 Million - $1.68 Million	18,280 New	18,280 $1.48 Million

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $198M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.